Gerresheimer (GXI) Given a €72.00 Price Target by Independent Research Analysts

Independent Research set a €72.00 ($83.72) price objective on Gerresheimer (ETR:GXI) in a research note published on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

GXI has been the topic of several other reports. Goldman Sachs Group set a €65.00 ($75.58) price objective on shares of Gerresheimer and gave the company a neutral rating in a report on Monday, February 11th. HSBC set a €68.00 ($79.07) target price on shares of Gerresheimer and gave the company a neutral rating in a research note on Wednesday, February 20th. Hauck & Aufhaeuser set a €50.00 ($58.14) target price on shares of Gerresheimer and gave the company a sell rating in a research note on Thursday, April 11th. Deutsche Bank set a €83.00 ($96.51) target price on shares of Gerresheimer and gave the company a buy rating in a research note on Tuesday, February 19th. Finally, JPMorgan Chase & Co. set a €49.50 ($57.56) target price on shares of Gerresheimer and gave the company a sell rating in a research note on Wednesday, January 30th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of €69.17 ($80.43).

GXI stock opened at €68.00 ($79.07) on Friday. The firm has a market capitalization of $2.14 billion and a PE ratio of 16.56. The company has a current ratio of 0.74, a quick ratio of 0.51 and a debt-to-equity ratio of 108.42. Gerresheimer has a 12 month low of €51.10 ($59.42) and a 12 month high of €80.25 ($93.31).

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Further Reading: Fiduciary

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.